Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications
Authors
Keywords
-
Journal
Expert Review of Pharmacoeconomics & Outcomes Research
Volume -, Issue -, Pages 1-14
Publisher
Informa UK Limited
Online
2021-02-05
DOI
10.1080/14737167.2021.1884546
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Implementing evidence-informed deliberative processes in health technology assessment: a low income country perspective
- (2020) Lydia Kapiriri et al. INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE
- Defining the concept of fair pricing for medicines
- (2020) Suerie Moon et al. BMJ-British Medical Journal
- New business models for research and development with affordability requirements are needed to achieve fair pricing of medicines
- (2020) Fatima Suleman et al. BMJ-British Medical Journal
- Use of record linkage to evaluate treatment outcomes and trial eligibility in a real‐world metastatic prostate cancer population in Scotland
- (2020) Kelly Baillie et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- Shift From Adalimumab Originator to Biosimilars in Denmark
- (2020) Thomas Bo Jensen et al. JAMA Internal Medicine
- Evidence Underlying Policy Proposals for Sustainable Anticancer Drug Prices
- (2020) Nora Franzen et al. JAMA Oncology
- Clinical benefit and cost of breakthrough cancer drugs approved by the US Food and Drug Administration
- (2020) Consolación Molto et al. CANCER
- Lessons From The Impact Of Price Regulation On The Pricing Of Anticancer Drugs In Germany
- (2020) Victoria D. Lauenroth et al. HEALTH AFFAIRS
- Towards a cancer mission in Horizon Europe: recommendations
- (2020) Anton Berns et al. Molecular Oncology
- Integrative Review of Managed Entry Agreements: Chances and Limitations
- (2020) Carolina Zampirolli Dias et al. PHARMACOECONOMICS
- From blockbuster to “nichebuster”: how a flawed legislation helped create a new profit model for the drug industry
- (2020) Daan Marselis et al. BMJ-British Medical Journal
- Exploring the status and views of managed entry agreements in Saudi Arabia: mixed-methods approach
- (2020) Hussain Abdulrahman Al-Omar et al. Expert Review of Pharmacoeconomics & Outcomes Research
- Cost-effectiveness analyses of breast cancer medications use in developing countries: a systematic review
- (2020) Nour Hisham Al-Ziftawi et al. Expert Review of Pharmacoeconomics & Outcomes Research
- Guiding principles for the use of knowledge bases and real-world data in clinical decision support systems: report by an international expert workshop at Karolinska Institutet
- (2020) Mikael Hoffmann et al. Expert Review of Clinical Pharmacology
- Biological Therapies in Immune-Mediated Inflammatory Diseases: Can Biosimilars Reduce Access Inequities?
- (2019) Daniel C. Baumgart et al. Frontiers in Pharmacology
- Beneluxa: What are the Prospects for Collective Bargaining on Pharmaceutical Prices Given Diverse Health Technology Assessment Processes?
- (2019) James F. O’Mahony PHARMACOECONOMICS
- Are Payers Ready, Willing, and Able to Provide Access to New Durable Gene Therapies?
- (2019) Jane F. Barlow et al. VALUE IN HEALTH
- The costs and benefits of pharmaceutical innovation: evidence from recent literature
- (2019) Roger Lee Mendoza JOURNAL OF MEDICAL ECONOMICS
- The Landscape of Cellular and Gene Therapy Products: Cost, Approvals, and Discontinuations
- (2019) Vaishali Shukla et al. Human Gene Therapy Clinical Development
- Data Resource Profile: The Systemic Anti-Cancer Therapy (SACT) Dataset
- (2019) Chloe J Bright et al. INTERNATIONAL JOURNAL OF EPIDEMIOLOGY
- Criteria Used for Priority-Setting for Public Health Resource Allocation in Low- and Middle-Income Countries: A Systematic Review
- (2019) Gunjeet Kaur et al. INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE
- Uncertainty and Cures: Discontinuation, Irreversibility, and Outcomes-Based Payments: What Is Different About a One-Off Treatment?
- (2019) Adrian Towse et al. VALUE IN HEALTH
- Medicine Shortages: Gaps Between Countries and Global Perspectives
- (2019) Angela Acosta et al. Frontiers in Pharmacology
- A proposal for value informed, affordable (“via”) prices for innovative medicines
- (2019) Lieven Annemans JOURNAL OF MEDICAL ECONOMICS
- The Use of Risk-Sharing Contracts in Healthcare: Theoretical and Empirical Assessments
- (2019) Fernando Antonanzas et al. PHARMACOECONOMICS
- Price Models for Multi-indication Drugs: A Systematic Review
- (2019) Carlos Campillo-Artero et al. Applied Health Economics and Health Policy
- Using GRADE methodology to assess innovation of new medicinal products in Italy
- (2019) Filomena Fortinguerra et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Multicriteria Decision Analysis to Support Health Technology Assessment Agencies: Benefits, Limitations, and the Way Forward
- (2019) Rob Baltussen et al. VALUE IN HEALTH
- Time to Review Authorisation and Funding for New Cancer Medicines in Europe? Inferences from the Case of Olaratumab
- (2019) Caridad Pontes et al. Applied Health Economics and Health Policy
- Value assessment of oncology drugs using a weighted criterion‐based approach
- (2019) Doreen A. Ezeife et al. CANCER
- Comprehensive value assessment of drugs using a multi-criteria decision analysis: An example of targeted therapies for metastatic colorectal cancer treatment
- (2019) Jason C. Hsu et al. PLoS One
- Multiple Criteria Decision Analysis for HTA across four EU Member States: Piloting the Advance Value Framework
- (2019) A. Angelis et al. SOCIAL SCIENCE & MEDICINE
- Introduction of the second-generation direct-acting antivirals (DAAs) in chronic hepatitis C: a register-based study in Sweden
- (2018) P. Frisk et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Negative Phase 3 Randomized Controlled Trials: Why cancer drugs fail the last barrier?
- (2018) Bishal Gyawali et al. INTERNATIONAL JOURNAL OF CANCER
- Outrageous prices of orphan drugs: a call for collaboration
- (2018) Lucio Luzzatto et al. LANCET
- Sustainability and affordability of cancer drugs: a novel pricing model
- (2018) Carin A. Uyl-de Groot et al. Nature Reviews Clinical Oncology
- Non-profit Drug Research and Development at a Crossroads
- (2018) Szymon Jarosławski et al. PHARMACEUTICAL RESEARCH
- Defining Elements of Value in Health Care—A Health Economics Approach: An ISPOR Special Task Force Report [3]
- (2018) Darius N. Lakdawalla et al. VALUE IN HEALTH
- Are life-extending treatments for terminal illnesses a special case? Exploring choices and societal viewpoints
- (2018) Neil McHugh et al. SOCIAL SCIENCE & MEDICINE
- Pilot study assessing the direct medical cost of treating patients with cancer in Kenya; findings and implications for the future
- (2018) Omondi Michelle Atieno et al. JOURNAL OF MEDICAL ECONOMICS
- Implementing Managed Entry Agreements in Practice: the Dutch reality check
- (2018) A. Makady et al. HEALTH POLICY
- Multi-Indication Pricing: Nice in Theory but Can it Work in Practice?
- (2018) Jorge Mestre-Ferrandiz et al. PHARMACOECONOMICS
- Fair global drug pricing
- (2018) Jonathan D. Campbell et al. Expert Review of Pharmacoeconomics & Outcomes Research
- Alternative State-Level Financing for Hepatitis C Treatment—The “Netflix Model”
- (2018) Mark R. Trusheim et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Real-World Use and Outcomes of Olaparib: a Population-Based Cohort Study
- (2018) Irene Eriksson et al. Targeted Oncology
- Consumer willingness to pay for a hypothetical Zika vaccine in Brazil and the implications
- (2018) Roberto Lúcio Muniz Júnior et al. Expert Review of Pharmacoeconomics & Outcomes Research
- Risk-Return Analysis of the Biopharmaceutical Industry as Compared to Other Industries
- (2018) Cedric Popa et al. Frontiers in Pharmacology
- Real-world evidence for coverage decisions: opportunities and challenges
- (2018) Grace Hampson et al. Journal of Comparative Effectiveness Research
- Using Post-market Utilisation Analysis to Support Medicines Pricing Policy: An Australian Case Study of Aflibercept and Ranibizumab Use
- (2018) Anna Kemp-Casey et al. Applied Health Economics and Health Policy
- The Economics of Indication-Based Drug Pricing
- (2017) Amitabh Chandra et al. NEW ENGLAND JOURNAL OF MEDICINE
- Performance-Based Risk-Sharing Arrangements: An Updated International Review
- (2017) Josh J. Carlson et al. PHARMACOECONOMICS
- The Implementation of Managed Entry Agreements in Central and Eastern Europe: Findings and Implications
- (2017) Alessandra Ferrario et al. PHARMACOECONOMICS
- Toward a Broader Concept of Value: Identifying and Defining Elements for an Expanded Cost-Effectiveness Analysis
- (2017) Louis P. Garrison et al. VALUE IN HEALTH
- Clinically meaningful benefit: real world use compared against the American and European guidelines
- (2017) Jessica J. Dreicer et al. Blood Cancer Journal
- Estimated generic prices of cancer medicines deemed cost-ineffective in England: a cost estimation analysis
- (2017) Andrew Hill et al. BMJ Open
- Cancer drugs: high price, uncertain value
- (2017) Deborah Cohen BMJ-British Medical Journal
- Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13
- (2017) Courtney Davis et al. BMJ-British Medical Journal
- Cost-effectiveness of vildagliptin for people with type 2 diabetes mellitus in Brazil; findings and implications
- (2017) Gustavo Laine Araujo De Oliveira et al. Expert Review of Pharmacoeconomics & Outcomes Research
- Cancer drugs: high price, uncertain value
- (2017) Deborah Cohen BMJ-British Medical Journal
- Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13
- (2017) Courtney Davis et al. BMJ-British Medical Journal
- Consumer Willingness to Pay for Dengue Vaccine (CYD-TDV, Dengvaxia®) in Brazil; Implications for Future Pricing Considerations
- (2017) Isabella P. Godói et al. Frontiers in Pharmacology
- The Early Awareness and Alert System in Sweden: History and Current Status
- (2017) Irene Eriksson et al. Frontiers in Pharmacology
- Managed Entry Agreements for Oncology Drugs: Lessons from the European Experience to Inform the Future
- (2017) Kim Pauwels et al. Frontiers in Pharmacology
- Adaptive Pathways: Possible Next Steps for Payers in Preparation for Their Potential Implementation
- (2017) Patricia Vella Bonanno et al. Frontiers in Pharmacology
- Assessment of Overall Survival, Quality of Life, and Safety Benefits Associated With New Cancer Medicines
- (2017) Sebastian Salas-Vega et al. JAMA Oncology
- Addressing the challenge of high-priced prescription drugs in the era of precision medicine: A systematic review of drug life cycles, therapeutic drug markets and regulatory frameworks
- (2017) Toon van der Gronde et al. PLoS One
- Policies for biosimilar uptake in Europe: An overview
- (2017) Evelien Moorkens et al. PLoS One
- Utilisation of the ESMO-MCBS in practice of HTA: Table 1.
- (2016) C. Wild et al. ANNALS OF ONCOLOGY
- Why Cancer?
- (2016) Alan Haycox PHARMACOECONOMICS
- Performance-Based Agreements in Italy: ‘Trendy Outcomes’ or Mere Illusions?
- (2016) Livio Garattini et al. PHARMACOECONOMICS
- Multi-Indication Pricing: Pros, Cons, And Its Applicability To The United Kingdom
- (2016) J Mestre-Ferrandiz et al. VALUE IN HEALTH
- Target prices for mass production of tyrosine kinase inhibitors for global cancer treatment
- (2016) Andrew Hill et al. BMJ Open
- Financial consequences of a payment-by-results scheme in Catalonia: gefitinib in advanced EGFR-mutation positive non-small-cell lung cancer
- (2016) Ana Clopes et al. JOURNAL OF MEDICAL ECONOMICS
- The Use of Surrogate and Patient-Relevant Endpoints in Outcomes-Based Market Access Agreements
- (2016) Mondher Toumi et al. Applied Health Economics and Health Policy
- In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs
- (2015) Ayalew Tefferi et al. MAYO CLINIC PROCEEDINGS
- Reimbursement Decisions for Pharmaceuticals in Sweden: The Impact of Disease Severity and Cost Effectiveness
- (2015) Mikael Svensson et al. PHARMACOECONOMICS
- Do the Current Performance-Based Schemes in Italy Really Work? “Success Fee”: A Novel Measure for Cost-Containment of Drug Expenditure
- (2015) Livio Garattini et al. VALUE IN HEALTH
- The Strength of Association Between Surrogate End Points and Survival in Oncology
- (2015) Vinay Prasad et al. JAMA Internal Medicine
- American Society of Clinical Oncology Perspective: Raising the Bar for Clinical Trials by Defining Clinically Meaningful Outcomes
- (2014) Lee M. Ellis et al. JOURNAL OF CLINICAL ONCOLOGY
- Sharing Risk between Payer and Provider by Leasing Health Technologies: An Affordable and Effective Reimbursement Strategy for Innovative Technologies?
- (2014) Richard Edlin et al. VALUE IN HEALTH
- Cancer Drugs in the United States: Justum Pretium—The Just Price
- (2013) Hagop M. Kantarjian et al. JOURNAL OF CLINICAL ONCOLOGY
- Paying for the Orphan Drug System: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments?
- (2012) Wills Hughes-Wilson et al. Orphanet Journal of Rare Diseases
- New Cystic Fibrosis Drug Offers Hope, at a Price
- (2012) J. Kaiser SCIENCE
- Multicriteria Decision Analysis for Including Health Interventions in the Universal Health Coverage Benefit Package in Thailand
- (2012) Sitaporn Youngkong et al. VALUE IN HEALTH
- Cost-Effectiveness Assessment of Orphan Drugs
- (2012) Steven Simoens et al. Applied Health Economics and Health Policy
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More